Rezolute, Inc. — Form 10-Q Summary
Business context and period: This is Rezolute’s unaudited fiscal first-quarter report for the three months ended September 30, 2023. The clinical-stage biopharmaceutical company is developing RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. It has no commercial products and has not generated revenue.
Financial results and liquidity
| Metric | Quarter ended September 30, 2023 | Prior-year quarter |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $12.2 million | $7.7 million |
| General and administrative expense | $3.7 million | $2.5 million |
| Operating loss | $15.9 million | $10.2 million |
| Net loss | $14.5 million | $9.8 million |
| Basic and diluted loss per share | $0.28 | $0.19 |
| Cash used in operating activities | $10.6 million | $7.6 million |
At September 30, 2023, cash and cash equivalents were $8.1 million, short-term marketable debt securities were $90.7 million, and long-term securities were $8.1 million. Working capital was approximately $95.5 million; total liabilities were $9.4 million. The company had no outstanding borrowings under its former loan agreement, which it repaid in 2022; it reported a $0.4 million embedded derivative liability and $2.3 million of operating lease liabilities. No operating margin is meaningful because the company had no revenue.
Material changes and operating cash flows
- R&D expense rose $4.5 million, or 59%, year over year, primarily from RZ358 Phase 3 readiness, including manufacturing, preclinical and clinical costs, and increased personnel costs. RZ402 Phase 2 costs also increased.
- G&A expense increased $1.2 million, or 47%, reflecting higher compensation, market research related to potential RZ358 launch preparation, and other costs.
- Net loss increased by $4.7 million. Interest and other income rose to $1.4 million from $0.4 million, mainly because of investment income; it partially offset operating expenses.
- Operating cash use increased by $3.0 million. Investing activities provided $2.6 million, primarily from security maturities net of purchases; there were no financing proceeds in the quarter.
- Available-for-sale debt securities had $290,000 of gross unrealized losses at quarter-end; the company reported no credit-loss allowance and did not sell securities before maturity.
Clinical outlook, risks and commitments
- Management planned to initiate the RZ358 sunRIZE Phase 3 study outside the U.S. in the fourth quarter of 2023, with topline results anticipated in the first half of 2025. European regulators agreed to a study that includes participants aged three months and older. The FDA maintained an age restriction of 12 years and older and an exposure cap, which the company said made U.S. participation infeasible for now; it is evaluating additional nonclinical work to address FDA concerns.
- RZ402 is in a Phase 2 study in diabetic macular edema. The company expected to complete enrollment in 2023 and provide an update before year-end.
- Management stated in one disclosure that existing resources were sufficient through at least November 2024; elsewhere, its current forecast indicated funding for planned activities through at least the third quarter of calendar 2025. The filing says additional financing will be needed for longer-term requirements.
- The company anticipated $10 million of potential XOMA Phase 3 milestones within the next 12 months, tied to RZ358 Phase 3 patient milestones, subject to clinical timing. The filing also describes up to $50 million of remaining clinical and regulatory milestones to XOMA and ActiveSite, and up to $202.5 million of potential commercialization-related milestones, plus royalties. These future payments depend on milestone achievement or commercialization.
- The filing identifies the Israel-Hamas conflict as a potential risk to planned RZ358 trial-site arrangements, which could require an alternative site and delay clinical data. It also discusses rat liver findings in nonclinical studies and the resulting FDA restrictions; the company believes those findings are unlikely to be relevant to humans, but that position has not eliminated FDA concerns.
- No material pending or threatened litigation was reported. Management assessed disclosure controls and procedures as effective as of September 30, 2023.
Important facts for investors to verify
- Confirm the clinical timelines and whether the sunRIZE Phase 3 study began as planned, including site selection and the FDA pathway.
- Reconcile the differing cash-runway statements: through November 2024 versus through the third quarter of calendar 2025, and assess the assumptions behind each.
- Check the timing and amount of XOMA milestones: the filing refers to first-patient dosing in one section and first-patient enrollment in another, and anticipates $10 million of potential payments within 12 months.
- Verify the October 2023 cashless warrant exercise and share count. The filing gives 2,797,404 shares in one section and 2,797,704 in another; it reports 39,625,271 common shares outstanding as of November 10, 2023.
- Monitor cash burn, financing needs, and investment portfolio credit and interest-rate risks; the company remains pre-revenue and expects operating losses to continue.